ABRAMS, K. L., P. F. STABILA, K. KAUPER u. S. ELLIOTT (2011):
Vascular endothelial growth factor in diabetic and nondiabetic canine cataract patients.
Vet. Ophthalmol. 14, 93-99
ACHEN, M. G., M. JELTSCH, E. KUKK, T. MAKINEN, A. VITALI, A. F. WILKS, K. ALITALO u. S. A. STACKER (1998):
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Proc. Natl. Acad. Sci. 95, 548-553
ADAMS, J., P. J. CARDER, S. DOWNEY, M. A. FORBES, K. MACLENNAN, V. ALLGAR, S.
KAUFMAN, S. HALLAM, R. BICKNELL, J. J. WALKER, F. CAIRNDUFF, P. J. SELBY, T. J.
PERREN, M. LANSDOWN u. R. E. BANKS (2000):
Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.
Cancer Res. 60, 2898-2905
AL-DISSI, A. N., D. M. HAINES, B. SINGH u. B. A. KIDNEY (2009):
Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor in canine cutaneous fibrosarcomas.
J. Comp. Pathol. 141, 229-236
ALON, T., I. HEMO, A. ITIN, J. PE'ER, J. STONE u. E. KESHET (1995):
Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.
Nat. Med. 1, 1024-1028
AMORIM, R. L., P. PINCZOWSKI, R. T. NETO u. S. C. RAHAL (2010):
Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours.
Vet. Comp. Oncol. 8, 23-27
75
ARESU, L., A. ARICO, S. COMAZZI, M. E. GELAIN, F. RIONDATO, M. MORTARINO, E.
MORELLO, D. STEFANELLO u. M. CASTAGNARO (2012):
VEGF and MMP-9: biomarkers for canine lymphoma.
Vet. Comp. Oncol. 12, 29-36
Article first published online: 10 APR 2012, DOI: 10.1111/j.1476-5829.2012.00328.x
BALLEGEER, E.A., FORREST, L.J., DICKINSON, R.M., SCHUTTEN, M.M., DELANEY, F.A., YOUNG, K.M. (2007):
Correlation of ultrasonographic appearance of lesions and cytologic and histologic diagnoses in splenic aspirates from dogs and cats: 32 cases (2002-2005).
J. Am. Vet. Med. Assoc. 230, 690-696
BANKS, R.E., FORBES, M.A., KINSEY, S.E., STANLEY, A., INGHAM, E., WALTERS, C., SELBY, P.J. (1998):
Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets:
significance for VEGF measurements and cancer biology.
Br. J. Cancer 77, 956-964
BARLEON, B., S. SOZZANI, D. ZHOU, H. A. WEICH, A. MANTOVANI u. D. MARME (1996):
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.
Blood 87, 3336-3343
BENAV, P., L. J. CROFFORD, R. L. WILDER u. T. HLA (1995):
Induction of Vascular Endothelial Growth-Factor Expression in Synovial Fibroblasts by Prostaglandin-E and Interleukin-1 - a Potential Mechanism for Inflammatory Angiogenesis.
Febs Lett. 372, 83-87
BERGERS, G. u. L. E. BENJAMIN (2003):
Tumorigenesis and the angiogenic switch.
Nat. Rev. Cancer 3, 401-410
76
BERSE, B., L. F. BROWN, L. VAN DE WATER, H. F. DVORAK u. D. R. SENGER (1992):
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.
Mol. Biol. Cell 3, 211-220
BRODEY, R. S., M. H. GOLDSCHMIDT u. J. R. ROSZEL (1983):
Canine Mammary-Gland Neoplasms.
J. Am. Anim. Hosp. Assoc. 19, 61-90
BROWN, N.O., PATNAIK, A.K., MACEWEN, E.G. (1985):
Canine Hemangiosarcoma - Retrospective Analysis of 104 Cases.
J. Am. Vet. Med. Assoc. 186, 56-58
BURGER, R. A., M. F. BRADY, M. A. BOOKMAN, G. F. FLEMING, B. J. MONK, H. HUANG, R. S. MANNEL, H. D. HOMESLEY, J. FOWLER, B. E. GREER, M. BOENTE, M. J. BIRRER u. S. X. LIANG (2011):
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N. Engl. J. Med. 365, 2473-2483
CAMPOS, A.G., CAMPOS, J.A.D.B., SANCHES, D.S., DAGLI, M.L.Z., MATERA, J.M.
(2012):
Immunohistochemical Evaluation of Vascular Endothelial Growth Factor (VEGF) in Splenic Hemangiomas and Hemangiosarcomas in Dogs.
J. Vet. Med. 2, 191-195
CAO, Y., P. LINDEN, J. FARNEBO, R. CAO, A. ERIKSSON, V. KUMAR, J. H. QI, L.
CLAESSON-WELSH u. K. ALITALO (1998):
Vascular endothelial growth factor C induces angiogenesis in vivo.
Proc. Natl. Acad. Sci. 95, 14389-14394
77
CARMELIET, P., V. FERREIRA, G. BREIER, S. POLLEFEYT, L. KIECKENS, M.
GERTSENSTEIN, M. FAHRIG, A. VANDENHOECK, K. HARPAL, C. EBERHARDT, C.
DECLERCQ, J. PAWLING, L. MOONS, D. COLLEN, W. RISAU u. A. NAGY (1996):
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.
Nature 380, 435-439
CLAUSS, M., M. GERLACH, H. GERLACH, J. BRETT, F. WANG, P. C. FAMILLETTI, Y. C.
PAN, J. V. OLANDER, D. T. CONNOLLY u. D. STERN (1990):
Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.
J. Exp. Med. 172, 1535-1545
CLIFFORD, C. A., D. HUGHES, M. W. BEAL, A. J. MACKIN, C. J. HENRY, F. S. SHOFER u. K. U. SORENMO (2001):
Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma.
J. Vet. Intern. Med. 15, 131-135
COHEN, T., D. NAHARI, L. W. CEREM, G. NEUFELD u. B. Z. LEVI (1996):
Interleukin 6 induces the expression of vascular endothelial growth factor.
J. Biol. Chem. 271, 736-741
COOPER, B.C., RITCHIE, J.M., BROGHAMMER, C.L.W., COFFIN, J., SOROSKY, J.I., BULLER, R.E., HENDRIX, M.J.C., SOOD, A.K. (2002):
Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer.
Clin. Cancer Res. 8, 3193-3197.
DE VRIES, C., J. A. ESCOBEDO, H. UENO, K. HOUCK, N. FERRARA u. L. T. WILLIAMS (1992):
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science 255, 989-991
78
DICKINSON, P. J., B. K. STURGES, R. J. HIGGINS, B. N. ROBERTS, C. M.
LEUTENEGGER, A. W. BOLLEN u. R. A. LECOUTEUR (2008):
Vascular endothelial growth factor mRNA expression and peritumoral edema in canine primary central nervous system tumors.
Vet. Pathol. 45, 131-139
DVORAK, H. F., M. DETMAR, K. P. CLAFFEY, J. A. NAGY, L. VAN DE WATER u. D. R.
SENGER (1995):
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
Int. Arch. Allergy Immunol. 107, 233-235
ESCUDIER, B., A. PLUZANSKA, P. KORALEWSKI, A. RAVAUD, S. BRACARDA, C.
SZCZYLIK, C. CHEVREAU, M. FILIPEK, B. MELICHAR, E. BAJETTA, V. GORBUNOVA, J.
O. BAY, I. BODROGI, A. JAGIELLO-GRUSZFELD u. N. MOORE (2007):
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Lancet 370, 2103-2111
FERRARA, N. (1999a):
Molecular and biological properties of vascular endothelial growth factor.
J. Mol. Med. 77, 527-543
FERRARA, N. (1999b):
Role of vascular endothelial growth factor in the regulation of angiogenesis.
Kidney Intern. 56, 794-814
FERRARA, N. (2004):
Vascular endothelial growth factor: basic science and clinical progress.
Endocr. Rev. 25, 581-611
79
FERRARA, N., K. CARVER-MOORE, H. CHEN, M. DOWD, L. LU, K. S. O'SHEA, L.
POWELL-BRAXTON, K. J. HILLAN u. M. W. MOORE (1996):
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.
Nature 380, 439-442
FERRARA, N. u. T. DAVIS-SMYTH (1997):
The biology of vascular endothelial growth factor.
Endocr. Rev. 18, 4-25
FERRARA, N. u. W. J. HENZEL (1989):
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.
Biochem. Biophys. Res. Commun. 161, 851-858
FERRARA, N., K. A. HOUCK, L. B. JAKEMAN, J. WINER u. D. W. LEUNG (1991):
The vascular endothelial growth factor family of polypeptides.
J. Cell. Biochem. 47, 211-218
FOLKMAN, J. (1971):
Tumor angiogenesis: therapeutic implications.
N. Engl. J. Med. 285, 1182-1186
FOLKMAN, J. (1975):
Tumor angiogenesis: a possible control point in tumor growth.
Ann. Intern. Med. 82, 96-100
FOLKMAN, J. (1985):
Tumor angiogenesis.
Adv. Cancer Res. 43, 175-203
FOLKMAN, J. (1990):
What is the evidence that tumors are angiogenesis dependent?
J. Natl. Cancer Inst. 82, 4-6
80 FOLKMAN, J. (1995):
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.
N. Engl. J. Med. 333, 1757-1763
FOLKMAN, J., E. MERLER, C. ABERNATHY u. G. WILLIAMS (1971):
Isolation of a tumor factor responsible for angiogenesis.
J. Exp. Med. 133, 275-288
FONG, G. H., J. ROSSANT, M. GERTSENSTEIN u. M. L. BREITMAN (1995):
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium.
Nature 376, 66-70
FONG, G. H., L. ZHANG, D. M. BRYCE u. J. PENG (1999):
Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice.
Development 126, 3015-3025
FRANK, S., G. HUBNER, G. BREIER, M. T. LONGAKER, D. G. GREENHALGH u. S.
WERNER (1995):
Regulation of vascular endothelial growth factor expression in cultured keratinocytes.
Implications for normal and impaired wound healing.
J. Biol. Chem. 270, 12607-12613
FUKUMURA, D., R. XAVIER, T. SUGIURA, Y. CHEN, E. C. PARK, N. LU, M. SELIG, G.
NIELSEN, T. TAKSIR, R. K. JAIN u. B. SEED (1998):
Tumor induction of VEGF promoter activity in stromal cells.
Cell 94, 715-725
81
GENTILINI, F., C. CALZOLARI, M. E. TURBA, C. AGNOLI, D. FAVA, M. FORNI u. P. F.
BERGAMINI (2005):
Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs.
Leuk. Res. 29, 1263-1269
GEORGE, M. L., S. A. ECCLES, M. G. TUTTON, A. M. ABULAFI u. R. I. SWIFT (2000):
Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?
Clin. Cancer Res. 6, 3147-3152
GERBER, H. P., V. DIXIT u. N. FERRARA (1998a):
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells.
J. Biol. Chem. 273, 13313-13316
GERBER, H. P., A. MCMURTREY, J. KOWALSKI, M. YAN, B. A. KEYT, V. DIXIT u. N.
FERRARA (1998b):
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.
J. Biol. Chem. 273, 30336-30343
GERBER, H. P., T. H. VU, A. M. RYAN, J. KOWALSKI, Z. WERB u. N. FERRARA (1999):
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation.
Nat. Med. 5, 623-628
GRAY, R., S. BHATTACHARYA, C. BOWDEN, K. MILLER u. R. L. COMIS (2009):
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer.
J. Clin. Oncol. 27, 4966-4972
82
GUNSILIUS, E., PETZER, A., STOCKHAMMER, G., NUSSBAUMER, W., SCHUMACHER, P., CLAUSEN, J., GASTL, G. (2000):
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood.
Oncol. 58, 169-174
HANAHAN, D. u. J. FOLKMAN (1996):
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell 86, 353-364
HEER, K., H. KUMAR, J. R. READ, J. N. FOX, J. R. MONSON u. M. J. KERIN (2001):
Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
Clin. Cancer Res. 7, 3491-3494
HOSGOOD, G. (1991):
Canine Hemangiosarcoma.
Comp. Cont. Educ. Pract. Vet. 13, 1065-1075
HURWITZ, H., FEHRENBACHER, L., NOVOTNY, W., CARTWRIGHT, T., HAINSWORTH, J., HEIM, J., BERLIN, A. BARON, S. GRIFFING, E. HOLMGREN, N. FERRARA, G. FYFE, B. ROGERS, R. ROSS u. F. KABBINAVAR (2004):
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
N. Engl. J. Med. 350, 2335-2342 JAIN, R. K. (2005):
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Science 307, 58-62
JELKMANN, W. (2001):
Pitfalls in the measurement of circulating vascular endothelial growth factor.
Clin. Chem. 47, 617-623
83
JOUKOV, V., K. PAJUSOLA, A. KAIPAINEN, D. CHILOV, I. LAHTINEN, E. KUKK, O.
SAKSELA, N. KALKKINEN u. K. ALITALO (1996):
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
EMBO J. 15, 290-298
KARAYIANNAKIS, A. J., K. N. SYRIGOS, A. POLYCHRONIDIS, A. ZBAR, G. KOURAKLIS, C. SIMOPOULOS u. G. KARATZAS (2002a):
Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.
Ann. Surg. 236, 37-42
KARAYIANNAKIS, A. J., K. N. SYRIGOS, A. ZBAR, N. BAIBAS, A. POLYCHRONIDIS, C.
SIMOPOULOS u. G. KARATZAS (2002b):
Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery.
Surgery 131, 548-555
KATO, Y., K. ASANO, T. MOGI, K. KUTARA, K. TESHIMA, K. EDAMURA, S. TSUMAGARI, A. HASEGAWA u. S. TANAKA (2007):
Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors.
J. Vet. Med. Sci. 69, 77-80
KENDALL, R. L. u. K. A. THOMAS (1993):
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
Proc. Natl. Acad. Sci. 90, 10705-10709
KIM, K. J., B. LI, J. WINER, M. ARMANINI, N. GILLETT, H. S. PHILLIPS u. N. FERRARA (1993):
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Nature 362, 841-844
84
KITADAI, Y., T. AMIOKA, K. HARUMA, S. TANAKA, M. YOSHIHARA, K. SUMII, N.
MATSUTANI, W. YASUI u. K. CHAYAMA (2001):
Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas.
Int. J. Cancer 93, 662-666
KOWANETZ, M. u. N. FERRARA (2006):
Vascular endothelial growth factor signaling pathways: therapeutic perspective.
Clin. Cancer Res. 12, 5018-5022
KUREBAYASHI, J., T. OTSUKI, H. KUNISUE, Y. MIKAMI, K. TANAKA, S. YAMAMOTO u.
H. SONOO (1999):
Expression of vascular endothelial growth factor (VEGF) family members in breast cancer.
Japn. J. Cancer Res. 90, 977-981
LEE, J.K., HONG, Y.J., HAN, C.J., HWANG, D.Y., HONG, S.I. (2000):
Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?
Int. J. Oncol. 17, 149-152
LEUNG, D. W., G. CACHIANES, W. J. KUANG, D. V. GOEDDEL u. N. FERRARA (1989):
Vascular endothelial growth factor is a secreted angiogenic mitogen.
Science 246, 1306-1309
LYTTLE, D. J., K. M. FRASER, S. B. FLEMING, A. A. MERCER u. A. J. ROBINSON (1994):
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus.
J. Virol. 68, 84-92
MAGLIONE, D., V. GUERRIERO, G. VIGLIETTO, P. DELLI-BOVI u. M. G. PERSICO (1991):
Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor.
Proc. Natl. Acad. Sci. 88, 9267-9271
85
MAIOLINI, A., M. OTTEN, M. HEWICKER-TRAUTWEIN, R. CARLSON u. A. TIPOLD (2013):
Interleukin-6, vascular endothelial growth factor and transforming growth factor beta 1 in canine steroid responsive meningitis-arteritis.
BMC Vet. Res. 9, 23
MAIOLINO, P., G. DE VICO u. B. RESTUCCI (2000):
Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin.
J. Comp. Pathol. 123, 141-145
MATIASEK, L. A., S. R. PLATT, V. ADAMS, T. J. SCASE, D. KEYS, J. MILLER, F. ADAMO, S. LONG u. K. MATIASEK (2009):
Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs.
J. Vet. Intern. Med. 23, 146-151
MILLANTA, F., V. CANESCHI, L. RESSEL, S. CITI u. A. POLI (2010):
Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma.
J. Comp. Pathol. 142, 36-42
MINCHENKO, A., T. BAUER, S. SALCEDA u. J. CARO (1994):
Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo.
Lab. Invest. 71, 374-379
MOHAMMED, R. A., A. GREEN, S. EL-SHIKH, E. C. PAISH, I. O. ELLIS u. S. G. MARTIN (2007):
Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis.
Br. J. Cancer 96, 1092-1100
86
NANKO, N., TANIKAWA, M., MASE, M., FUJITA, M., TATEYAMA, H., MIYATI, T., YAMADA, K. (2009):
Involvement of Hypoxia-Inducible Factor-1 alpha and Vascular Endothelial Growth Factor in the Mechanism of Development of Chronic Subdural Hematoma.
Neurol. Med.Chir. 49, 379-385
NG, E. W., D. T. SHIMA, P. CALIAS, E. T. CUNNINGHAM, JR., D. R. GUYER u. A. P.
ADAMIS (2006):
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
Nat. Rev. Drug Discov. 5, 123-132
OLOFSSON, B., K. PAJUSOLA, A. KAIPAINEN, G. VON EULER, V. JOUKOV, O.
SAKSELA, A. ORPANA, R. F. PETTERSSON, K. ALITALO u. U. ERIKSSON (1996):
Vascular endothelial growth factor B, a novel growth factor for endothelial cells.
Proc. Natl. Acad. Sci. 93, 2576-2581
OLSSON, A. K., A. DIMBERG, J. KREUGER u. L. CLAESSON-WELSH (2006):
VEGF receptor signalling - in control of vascular function.
Nat. Rev. Mol. Cell Biol. 7, 359-371
OWEN, L. N. (1979):
A comparative study of canine and human breast cancer.
Invest. Cell Pathol. 2, 257-275
PARK, J. E., H. H. CHEN, J. WINER, K. A. HOUCK u. N. FERRARA (1994):
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
J. Biol. Chem. 269, 25646-25654
PEPPER, M. S., S. J. MANDRIOTA, M. JELTSCH, V. KUMAR u. K. ALITALO (1998):
Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity.
J. Cell. Physiol. 177, 439-452
87
PERTOVAARA, L., A. KAIPAINEN, T. MUSTONEN, A. ORPANA, N. FERRARA, O.
SAKSELA u. K. ALITALO (1994):
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.
J. Biol. Chem. 269, 6271-6274
PLATE, K. H., G. BREIER, H. A. WEICH u. W. RISAU (1992):
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.
Nature 359, 845-848
PLATT, S. R., T. J. SCASE, V. ADAMS, L. WIECZOREK, J. MILLER, F. ADAMO u. S. LONG (2006):
Vascular endothelial growth factor expression in canine intracranial meningiomas and association with patient survival.
J. Vet. Intern. Med. 20, 663-668
POON, R.T., LAU, C.P., CHEUNG, S.T., YU, W.C., FAN, S.T. (2003):
Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma.
Cancer Res. 63, 3121-3126
PRYMAK, C., MCKEE, L.J., GOLDSCHMIDT, M.H., GLICKMAN, L.T. (1988):
Epidemiologic, Clinical, Pathologic, and Prognostic Characteristics of Splenic Hemangiosarcoma and Splenic Hematoma in Dogs - 217 Cases (1985).
J. Am. Vet. Med. Assoc. 193, 706-712
QIU, C., D. D. LIN, H. H. WANG, C. H. QIAO, J. WANG u. T. ZHANG (2008a):
Quantification of VEGF-C expression in canine mammary tumours.
Aust. Vet. J. 86, 279-282
88
QIU, C. W., D. G. LIN, J. Q. WANG, C. Y. LI u. G. Z. DENG (2008b):
Expression and significance of PTEN and VEGF in canine mammary gland tumours.
Vet. Res. Commun. 32, 463-472
RAHIMI, N., V. DAYANIR u. K. LASHKARI (2000):
Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells.
J. Biol. Chem. 275, 16986-16992
REBUZZI, L., M. WILLMANN, K. SONNECK, K. V. GLEIXNER, S. FLORIAN, R. KONDO, M.
MAYERHOFER, A. VALES, A. GRUZE, W. F. PICKL, J. G. THALHAMMER u. P. VALENT (2007):
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
Vet. Immunol. Immunopathol. 115, 320-333
RISAU, W. u. I. FLAMME (1995):
Vasculogenesis.
Annu. Rev. Cell Dev. Biol. 11, 73-91
RISSANEN, T. T., J. E. MARKKANEN, M. GRUCHALA, T. HEIKURA, A. PURANEN, M. I.
KETTUNEN, I. KHOLOVA, R. A. KAUPPINEN, M. G. ACHEN, S. A. STACKER, K. ALITALO u. S. YLA-HERTTUALA (2003):
VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses.
Circ. Res. 92, 1098-1106
ROBINSON, C. J. u. S. E. STRINGER (2001):
The splice variants of vascular endothelial growth factor (VEGF) and their receptors.
J. Cell Sci. 114, 853-865
89 ROSEN, L. S. (2002):
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
Cancer Control 9, 36-44
ROSENFELD, P. J., D. M. BROWN, J. S. HEIER, D. S. BOYER, P. K. KAISER, C. Y.
CHUNG u. R. Y. KIM (2006):
Ranibizumab for neovascular age-related macular degeneration.
N. Engl. J. Med. 355, 1419-1431
ROSSMEISL, J. H., R. B. DUNCAN, W. R. HUCKLE u. G. C. TROY (2007):
Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms.
Am. J. Vet. Res. 68, 1239-1245
SALGADO, R., BENOY, I., BOGERS, J., WEYTJENS, R., VERMEULEN, P., DIRIX, L., VAN MARCK, E. (2001):
Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study.
Angiogenesis 4, 37-43.
SALVEN, P., ORPANA, A., JOENSUU, H. (1999):
Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor.
Clin. Cancer Res. 5, 487-491
SALVEN, P., T. RUOTSALAINEN, K. MATTSON u. H. JOENSUU (1998):
High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer.
Int. J. Cancer 79, 144-146
90
SALVEN, P., L. TEERENHOVI u. H. JOENSUU (1997):
A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma.
Blood 90, 3167-3172
SANDLER, A., R. GRAY, M. C. PERRY, J. BRAHMER, J. H. SCHILLER, A. DOWLATI, R.
LILENBAUM u. D. H. JOHNSON (2006):
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
N. Engl. J. Med. 355, 2542-2550
SCHEIDEGGER, P., W. WEIGLHOFER, S. SUAREZ, B. KASER-HOTZ, R. STEINER, K.
BALLMER-HOFER u. R. JAUSSI (1999):
Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs.
Biol. Chem. 380, 1449-1454
SEKIS, I., W. GERNER, M. WILLMANN, L. REBUZZI, A. TICHY, M. PATZL, J. G.
THALHAMMER, A. SAALMULLER u. M. M. KLEITER (2009):
Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line.
Am. J. Vet. Res. 70, 1141-1150
SENGER, D. R., S. J. GALLI, A. M. DVORAK, C. A. PERRUZZI, V. S. HARVEY u. H. F.
DVORAK (1983):
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.
Science 219, 983-985
SHALABY, F., J. ROSSANT, T. P. YAMAGUCHI, M. GERTSENSTEIN, X. F. WU, M. L.
BREITMAN u. A. C. SCHUH (1995):
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.
Nature 376, 62-66
91
SHEN, B. Q., D. Y. LEE, H. P. GERBER, B. A. KEYT, N. FERRARA u. T. F. ZIONCHECK (1998):
Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro.
J. Biol. Chem. 273, 29979-29985
SHIBUYA, M., S. YAMAGUCHI, A. YAMANE, T. IKEDA, A. TOJO, H. MATSUSHIME u. M.
SATO (1990):
Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.
Oncogene 5, 519-524
SHIMADA, H., A. TAKEDA, Y. NABEYA, S. I. OKAZUMI, H. MATSUBARA, Y. FUNAMI, H.
HAYASHI, Y. GUNJI, S. KOBAYASHI, T. SUZUKI u. T. OCHIAI (2001):
Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.
Cancer 92, 663-669
SHIOMITSU, K., C. L. JOHNSON, D. E. MALARKEY, A. F. PRUITT u. D. E. THRALL (2009):
Expression of epidermal growth factor receptor and vascular endothelial growth factor in malignant canine epithelial nasal tumours.
Vet. Comp. Oncol. 7, 106-114
SHWEIKI, D., A. ITIN, D. SOFFER u. E. KESHET (1992):
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
Nature 359, 843-845
SILVERSTEIN, D. C., C. MONTEALEGRE, F. S. SHOFER u. C. M. OTTO (2009):
The association between vascular endothelial growth factor levels and clinically evident peripheral edema in dogs with systemic inflammatory response syndrome.
J. Vet. Emerg. Crit. Care 19, 459-466
92 SOBCZYNSKA-RAK, A. (2009):
Correlation between Plasma Vegf and Angiogenesis of Skin and Subcutaneous Tissue Cancer in Dogs.
Bull. Vet. Inst. Pulawy 53, 503-508
SPANGLER, W.L., CULBERTSON, M.R. (1992):
Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989).
J. Am. Vet. Med. Assoc. 200, 829-834
SPANGLER, W.L., KASS, P.H. (1997):
Pathologic factors affecting postsplenectomy survival in dogs.
J. Vet. Intern. Med. 11, 166-171
TALAR-WOJNAROWSKA, R., GASIOROWSKA, A., OLAKOWSKI, M., LEKSTAN, A., LAMPE, P., SMOLARZ, B., ROMANOWICZ-MAKOWSKA, H., KULIG, A., MALECKA-PANAS, E. (2010):
Vascular endothelial growth factor (VEGF) genotype and serum concentration in patients with pancreatic adenocarcinoma and chronic pancreatitis.
J. Physiol. Pharmacol. 61, 711-716
TAYLOR, K. H., A. N. SMITH, M. HIGGINBOTHAM, D. D. SCHWARTZ, D. M. CARPENTER u. E. M. WHITLEY (2007):
Expression of vascular endothelial growth factor in canine oral malignant melanoma.
Vet. Comp. Oncol. 5, 208-218
TERMAN, B. I., M. E. CARRION, E. KOVACS, B. A. RASMUSSEN, R. L. EDDY u. T. B.
SHOWS (1991):
Identification of a new endothelial cell growth factor receptor tyrosine kinase.
Oncogene 6, 1677-1683
THAMM, D.H., O'BRIEN, M.G., VAIL, D.M. (2008):
Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma.
Vet. Comp. Oncol. 6, 126-132
93
TROY, G. C., W. R. HUCKLE, J. H. ROSSMEISL, D. PANCIERA, O. LANZ, J. L.
ROBERTSON u. D. L. WARD (2006):
Endostatin and vascular endothelial growth factor concentrations in healthy dogs, dogs with selected neoplasia, and dogs with nonneoplastic diseases.
J. Vet. Intern. Med. 20, 144-150
TUDER, R. M., B. E. FLOOK u. N. F. VOELKEL (1995):
Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.
J. Clin. Invest. 95, 1798-1807
UEDA, T., TAKEYAMA, Y., YASUDA, T., MATSUMURA, N., SAWA, H., NAKAJIMA, T., KURODA, Y. (2006):
Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis.
J. Surg. Res. 134, 223-230
VALTOLA, R., SALVEN, P., HEIKKILÄ, P., TAIPALE, J., JOENSUU, H., REHN, M., PIHLAJANIEMI, T., WEICH, H., DEWAAL, R., ALITALO, K. (1999):
VEGFR-3 and Its Ligand VEGF-C Are Associated with Angiogenesis in Breast Cancer.
Am. J. Pathol. 154, 1381-1390
VERHEUL, H.M., HOEKMAN, K., LUYKX-DE BAKKER, S., EEKMAN, C.A., FOLMAN, C.C., BROXTERMAN, H.J., PINEDO, H.M. (1997):
Platelet: transporter of vascular endothelial growth factor.
Clin. Cancer Res. 3, 2187-2190
VINCENTI, V., C. CASSANO, M. ROCCHI u. G. PERSICO (1996):
Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.
Circulation 93, 1493-1495
94 WANG, G. L. u. G. L. SEMENZA (1995):
Purification and characterization of hypoxia-inducible factor 1.
J. Biol. Chem. 270, 1230-1237
WARREN, R. S., H. YUAN, M. R. MATLI, N. FERRARA u. D. B. DONNER (1996):
Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma.
J. Biol. Chem. 271, 29483-29488
WEBB, N.J., BOTTOMLEY, M.J., WATSON, C.J., BRENCHLEY, P.E. (1998):
Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting:
implications for measurement of circulating VEGF levels in clinical disease.
Clin. Sci. 94, 395-404
WERGIN, M. C. u. B. KASER-HOTZ (2004):
Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours.
In Vivo 18, 15-19
WILLETT, C. G., Y. BOUCHER, E. DI TOMASO, D. G. DUDA, L. L. MUNN, R. T. TONG, D.
C. CHUNG, D. V. SAHANI, S. P. KALVA, S. V. KOZIN, M. MINO, K. S. COHEN, D. T.
SCADDEN, A. C. HARTFORD, A. J. FISCHMAN, J. W. CLARK, D. P. RYAN, A. X. ZHU, L.
S. BLASZKOWSKY, H. X. CHEN, P. C. SHELLITO, G. Y. LAUWERS u. R. K. JAIN (2004):
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nat. Med. 10, 145-147
WOLFESBERGER, B., A. GUIJA DE ARESPACOHAGA, M. WILLMANN, W. GERNER, I.
MILLER, I. SCHWENDENWEIN, M. KLEITER, M. EGERBACHER, J. G. THALHAMMER, L.
MUELLAUER, M. SKALICKY u. I. WALTER (2007):
Expression of vascular endothelial growth factor and its receptors in canine lymphoma.
J. Comp. Pathol. 137, 30-40
95
YAMAMOTO, Y., M. TOI, S. KONDO, T. MATSUMOTO, H. SUZUKI, M. KITAMURA, K.
TSURUTA, T. TANIGUCHI, A. OKAMOTO, T. MORI, M. YOSHIDA, T. IKEDA u. T.
TOMINAGA (1996):
Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients.
Clin. Cancer Res. 2, 821-826
YAMAZAKI, Y., Y. MATSUNAGA, Y. TOKUNAGA, S. OBAYASHI, M. SAITO u. T. MORITA (2009):
Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species.
J. Biol. Chem. 284, 9885-9891
YLA-HERTTUALA, S., T. T. RISSANEN, I. VAJANTO u. J. HARTIKAINEN (2007):
Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine.
J. Am. Coll. Cardiol. 49, 1015-1026
YONEMARU, K., H. SAKAI, M. MURAKAMI, T. YANAI u. T. MASEGI (2006):
Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors.
Vet. Pathol. 43, 971-980
96